#ESMO26: Investigational bispecific antibodies, such as the anti-PD-L1/VEGF-A pumitamig, are showing promise when combined with antibody–drug conjugates (#ADCs) in advanced solid t

ESMO - Eur. Oncology· @myESMO · X·2026-10-24 21:45· 20 hours agoScore45

Body · original

#ESMO26: Investigational bispecific antibodies, such as the anti-PD-L1/VEGF-A pumitamig, are showing promise when combined with antibody–drug conjugates (#ADCs) in advanced solid tumours, as discussed by Funda Meric-Bernstam

🔗 https://ow.ly/l98f50ZZkgJ

#InsightsbyESMO

199 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

1963Pmatched by Investigational immunotherapy

First-in-human phase I study of GB268, a tri-specific antibody targeting PD-1, CTLA-4 and VEGF in advanced solid tumours

https://esmocongress.esmo.org

2660Pmatched by NSCLC, metastatic

Phase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results

https://esmocongress.esmo.org

3636TIPmatched by Renal cancer

LITESPARK-034: Phase 3 study of belzutifan plus zanzalintinib versus belzutifan in participants with advanced renal cell carcinoma (RCC) during or after anti-PD-(L)1 therapy and VEGF-TKI

https://esmocongress.esmo.org

Source: ESMO - Eur. Oncology · x.com